Details

Autor(en) / Beteiligte

• Tohda, Yuji
• Iwanaga, Takashi
• Sano, Hiroyuki
• Kume, Hiroaki
• Hirata, Kazuto
• Ohkura, Noriyuki
• Tachibana, Isao
• Nishimura, Yoshihiro
• Matsumoto, Hisako
• Minakata, Yoshiaki
• Yoshikawa, Masanori
• Fujimura, Masaki

Titel

Improved quality of life in asthma patients under long‐term therapy: Assessed by AHQ‐Japan

Ist Teil von

• International journal of clinical practice (Esher), 2017-01, Vol.71 (1), p.e12898-n/a

Ort / Verlag

England: Hindawi Limited

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Summary Background and objectives Assessment of the effects of long‐term management on patient quality of life (QOL) would be extremely useful for determining asthma treatment strategies. However, no studies have evaluated QOL over an extended period of time. This study evaluated the changes in QOL, drug management and disease severity in the same asthma patients at an interval of approximately 9 years. Methods We re‐surveyed asthma patients enrolled in a survey conducted in 2004 to evaluate the effects of approximately a decade of treatment on disease severity and QOL assessed by the Japanese Asthma Health Questionnaire (AHQ‐JAPAN). Results A total of 2179 patients were enrolled in the study from 93 centres, and 1332 patients were included in the per‐protocol analysis. Usage rates of inhaled corticosteroids (ICS) for treatment of stable asthma were over 90% at both time points. The AHQ‐JAPAN total score improved significantly from 22.2±19.7 in 2004 to 19.7±19.9 in 2013 (P<.001). Significant improvements were also observed in 5 of 6 subscales of AHQ‐JAPAN, with Social Activity constituting the sole exception. Conclusions Asthma severity declined and QOL assessed by AHQ‐JAPAN improved, which is considered as a reflection of improved asthma control at least partly attributable to widespread use of anti‐inflammatory drugs as represented by ICS. The study also revealed the presence of those with poor QOL, especially in patients with concomitant respiratory diseases, and an increase in severe persistent asthma cases, warranting further long‐term efforts at improving QOL. Trial registration number: UMIN 000010483.